I de oprindelige kliniske forsøg (Fase II/ III) blev der rapporteret bivirkninger med mulig, sandsynlig eller ukendt relation til ritonavir hos ≥2% af 1033 patienter:
In the original clinical studies (Phase II/III), adverse events with possible, probable or unknown relationship to ritonavir were reported in ≥ 2% of 1033 patients.